Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
AIDS Behav. Author manuscript; available in PMC 2012 May 22.
Published in final edited form as:
PMCID: PMC3357499

Change in Sexual Activity 12 Months After ART Initiation Among HIV-Positive Mozambicans


We assessed sexual behaviors before and 12-months after ART initiation among 277 Mozambicans attending an HIV clinic. Measured behaviors included the number of sexual partners, condom use, concurrent relationships, disclosure of HIV status, alcohol use, and partners’ serostatus. Compared to before ART initiation, increases were seen 12 months after ART in the proportion of participants who were sexually active (48% vs. 64% respondents, P < 0.001) and the proportion of participants with HIV-negative or unknown serostatus partners (45% vs. 80%, P < 0.001). Almost all (96%) concurrent partnerships reported at 12 months formed after ART initiation. Although reported correct and consist condom use increased, the number of unprotected sexual relationships remained the same (n = 45). Non-disclosure of HIV-serostatus to sexual partners was the only significant predictor of practicing unprotected sex with partners of HIV-negative or unknown serostatus. Sexual activity among HIV-positive persons on ART increased 12 months after ART initiation. Ongoing secondary transmission prevention programs addressing sexual activity with multiple partners, disclosure to partners and consistent condom use with serodisconcordant partners must be incorporated throughout HIV care programs.

Keywords: Antiretroviral therapy (ART), HIV/AIDS, Africa, Sexual behavior, Concurrency, Unprotected sex


The expansion of antiretroviral therapy (ART) in low-income countries has improved the health of HIV-positive individuals and their communities [1, 2] by reducing progression to AIDS and death [35] and lowering infectivity by lowering viral load in plasma, semen, and vaginal fluid [6, 7]. However, for every person initiating ART in resource-limited settings it is estimated that there are four more newly-infected persons [8]. Individuals on ART feel better and live longer with HIV, both of which increase the potential for more sexual activity leading to secondary HIV transmission. A number of factors may influence secondary HIV transmission risk, including health beliefs [9], HIV treatment optimism or complacency (e.g., that non-detectable virus equates with inability to transmit HIV) [10, 11] or cultural norms regarding gender-specific sexual behaviors. Other factors may include lack of disclosure of HIV status, community stigma around HIV and alcohol and substance use that may increase unsafe sexual practices.

Though some evidence from Uganda [12, 13] and North America [14, 15], and transmission mathematical modeling [16, 17] show that increased ART coverage can reduce secondary HIV transmission, it remains postulated that behavioral disinhibition [18] and insufficient ART adherence [18] could erase the gains made by ART at the population level. In high-income countries such as the United States (US), where HIV incidence plateaued for over a decade, the number of new infections is estimated to have increased from 40,000 to 65,000 infections annually [19]. Increases in sexually transmitted infections (STIs) and sexual risk behaviors have been seen among HIV-positive men who have sex with men [2022] including syphilis outbreaks in San Francisco [23]. Unprotected sex with discordant partners is common in Africa, with its mature and generalized HIV epidemics. In Mozambique we found that among individuals starting ART in 2004–2006, 65% of pre-ART sex acts were unprotected and only 45% disclosed their HIV status to partners [24]. Similarly, several studies from Africa have found an increase in high risk sexual behavior among persons initiating ART [25, 26]. Other studies found no increase [2729] or a decrease in high risk sexual behavior 1 year after ART [12, 30, 31]. This study coupled with recent findings from Africa regarding the association of ART and secondary HIV transmission risk [2527, 30, 32] will help identify patterns of high risk sexual behavior and help guide prevention with positive strategies. We therefore examined the sexual behaviors reported among 277 HIV-positive Mozambican men and women in the 3 months prior to ART initiation, and 12 months later.


Participants and Setting

The study was conducted between October, 2004 and May, 2006 at the HIV care clinic in the Beira Central Hospital, a large-volume public institution providing free specialized HIV care and antiretroviral medications to all affected Mozambicans in Beira and the surrounding area. Clinic staff assessed patients’ ART eligibility based on standard Mozambican norms for starting therapy (CD4 < 200/mm3 regardless of WHO stage, CD4 200–349/mm3 if in WHO stage 3 or pregnant, and WHO stage 4 regardless of CD4 count). The staff pharmacist attempted to refer all persons initiating ART to the study team. The research manager, in consultation with clinic staff, assessed the eligibility of potential participants according to the following criteria: at least 18 years of age, living near the clinic, and free of severe mental illness or dementia (as assessed by clinic staff). The study protocol was reviewed and approved by the Institutional Review Boards of the Mozambique Ministry of Health and the University of Washington. All participants provided written consent (see [24]).


During the study recruitment period, 683 people initiated ART, 433 were eligible for the study, and 350 were enrolled on the day they started ART. As part of the primary study aim, participants were randomly assigned to either a modified directly observed therapy adherence intervention or standard care, and completed a 45-min interviewer–administered questionnaire [33, 34]. As part of the secondary aim, which is reported in this paper, participants reported their sexual behaviors during the 3 months prior to the day they initiated ART and during the 3 months prior to the 12-month assessment point. Interviewers attended a 5-day training and interviews were conducted in the local language. Participants were reimbursed 25,000 meticais (approximately US$1) for each interview.


Most items and all scales were selected from published and validated measures and all items were transcribed and pre-tested, and psychometric properties for validity and reliability were assessed for cultural appropriateness in Beira, Mozambique [33].

Sexual Behavior

We asked respondents about the number of sexual partners 12 months prior to and 12 months after initiating ART. At each assessment point, we assessed number and type of sex acts (i.e., oral, anal, or vaginal) for each of the participants’ last three sexual partners in the last 3 months, and the frequency of correct and consistent condom use (i.e., number of times condoms were used minus breakage, slippage, or incorrect application). To assess concurrent relationships, participants provided the month, day, and year the relationship began and ended. Any overlap in the last 12 month with two or more partners was coded as a concurrent relationship. To validate this measure, participants were also asked “About how many other sexual partners did you have during the time you were together?” There were no discrepancies between the overlap dates and the response to this single item question. If more than three partners were reported in the 3 month assessment timeframe, summary questions were used to capture the number of partners, sex acts, and condom use per sex act for the other partners. To calculate a correct and consistent score, we set mechanical (not user-related) condom effectiveness at 0.95 to take into account product defects and then adjusted this rate by the number of times a participant reported the condom broke, slipped off, or was put on incorrectly in the prior 3 months. The ‘correct & consistent condom use score’ ranged from 0 (poor or non use) to 0.95 (perfect and consistent use) [24].

Treatment Optimism (Complacency)

This measure is defined as “minimizing, discounting, or discrediting the threat of HIV/AIDS” [11, p. 427]. Two sets of culturally adapted measures assessed prevention-related attitudes and perceptions of ART medication. Participants responded to 5 items on their attitudes about HIV/AIDS since ART treatment, including HIV/AIDS being less of a threat, less worry about transmitting HIV, believing there is now nearly a cure, HIV/AIDS is less serious than in the past, and being HIV-positive is not a big problem now that treatment is available [10, 35, 36]. The standardized Cronbach’s α for this sample was 0.73. A second six-item scale captured whether participants felt it was necessary to practice safer sex after initiating ART (α = 0.66). Response to each item was made on a 4-point response scale ranging from strongly disagree to strongly agree. A score for each scale was created. The summative score was divided by the number of items over which the sum was calculated. Treatment optimism items were added after the study began; thus only 201 participants responded.

To capture culturally appropriate social and cultural factors that may influence individuals’ perception and understanding of health risk, participants responded to 10 items about men’s and women’s sexual roles in Mozambique society. Items asked the participants to rate the validity of a statement in relation to both genders, such as, “a married man/woman can have one or more sexual partner(s) than the person they are married to; a single man/woman can have one or more sexual partners while dating another person; and men/women want more sex than women/men”. Gender specific items included: “women having multiple male partners is an economic necessity; there are more women than men so men are expected to have multiple partners; and a man is obligated to have multiple partners.” Response options were graded on a 4-point Likert scale ranging from “strongly disagree” to “strongly agree” (α = 0.87).

A 21-item stigma scale, reduced from Berger et al. 40-item scale [37], captured the social and emotional aspects of people living with HIV. This scale has been used in several studies throughout southern and eastern Africa with good validity and reliability [38, 39]. The items include social or public stigma (items relating to fear and rejection, such as what “most people think about a person with HIV” or what “most people with HIV can expect when others learn they have HIV”); negative self-image (items expressing “feelings of shame and guilt such as feeling unclean, not as good as others, or like a bad person because of HIV”); and personalized stigma (items relating to personal experiences or fears of rejection for having HIV, such as “losing friends, feeling that people were avoiding him/her, and regrets for having told some people”). Higher scores range from 21 to 84 with scores indicating higher levels of stigma. The overall scale α = 0.90 for this population [37].


Variables such as gender, age, income, employment status, and education were recorded at baseline; income and employment status were reassessed at 12 months after baseline via questionnaire.

Clinical Measures

Participants provided a 4–5 ml blood sample for a CD4 cell count as part of standard care immediately prior to ART and 4 and 10 months after initiating ART. The absolute CD4 cell count was determined through flow cytometry. A chart review was conducted to record the CD4 test result closest to but within 2 months of the assessment point. If a CD4 result was not available during this time frame, the participant was excluded from this analysis (missing at 12 months n = 31).

Alcohol Use

If participants indicated alcohol or drugs use, they were asked a two-item screening for alcohol and substance abuse. In the past 12 months… “did you drink alcohol or used drugs more than you meant to” and “did you feel the need to cut down on your drinking or drug use?” [40].

Sexual Partner Characteristics

For each of their last three sexual partners, participants provided basic socio-demographic data, HIV status (status unknown or known to have tested positive or negative), and approximate start and end dates to capture concurrent relationships. Among those that were married, we assessed whether concurrent relationships occurred outside the marriage, to account for legal polygamous marriages.

Statistical Methods

We assessed change in sexual activity (sexual behavior, sexual partner characteristics) from time 1 (3 months prior to ART initiation) and time 2 (3 months prior to the 12 month assessment point) and factors (disclosure of HIV status, alcohol use, and socioeconomic variables) associated with sexual behavior. To assess change in the baseline and the 12-month measures, differences in continuous variables were tested using two-sided paired t tests or Wilcoxon rank sum tests if the data were highly skewed. Associations between categorical data variables were assessed using the McNemar test to compare proportions. When assessing factors associated with sexual behavior 12 months after ART initiation, we used the independent t test and Pearson chi-square as appropriate. We examined factors associated with reported concurrent relationships and unprotected sex with partners whose serostatus was HIV-negative or unknown (assessed as separate outcomes) by fitting a logistic multivariable regression model including variables significant at the P = 0.05 level in bivariate analyses. All analyses were conducted using two-sided tests and a significance level of 0.05.



At baseline, 350 HIV-positive persons starting ART were interviewed. At the 12 month assessment point, 55 participants had died, and an additional 18 participants were lost to follow-up. Of the remaining 277 participants included in these analyses, 100% reported only heterosexual relationships, 7% any anal sex, and 8% any oral sex. Men were older than women (Median 39: IQR 21, 45 compared to Mdn = 32, IQR = 27, 37, respectively: difference 6.6 years, 95% confidence interval 4.7–8.4). Compared to the time of ART initiation, more participants at 12 months after ART were employed (71% vs. 80%, χ2 = 11.7, P < 0.001) and had disclosed their HIV status to their sexual partner (58% vs. 73%, χ2 = 3.89, P < 0.001), and less reported substance use (36% vs. 21%, χ2 = 19.1, P < 0.001; see Table 1).

Table 1
Socio-economic, clinical, sexual behavior and complacency score characteristics of the 277 HIV-positive participants at ART initiation and 12 months after ART initiation

Change in Sexual Activity from Time 1 to Time 2

Of the 277 participants (see Table 1), 48% (n = 133) reported sexual activity at time 1, while 64% (n = 177) reported sexual activity at time 2 (χ2 = 21.0, P < 0.001). Of these, 39% (n = 109) reported sexually active at both assessment points with no difference in the mean number of partners (1.20 at baseline vs. 1.15 at 12 months). It is important to note that although the mean is similar, the number of actual partners increased as 133 sexually active participants at time 1 reported 157 partners while 12 months later 177 sexually active participants reported 210 partners. Additionally, there was an increase in the number of respondents whose partner’s HIV status was negative or unknown (45% vs. 80%, χ2 = 22.2, P < 0.001). There was no difference in sexual activity between those randomized to modified directly observed therapy or standard care.

As compared to time 1, at time 2, respondents reported higher correct and consistent condom use (mean scores 0.36 vs. 0.77, t = 8.21, P < 0.001). The number of respondents reporting unprotected sex with HIV-negative or unknown status person remained unchanged (34%, n = 45 vs. 25%, n = 45, t = 1.71) with only five respondents reporting the same behavior at time 1.

There was no significant difference in the proportion of participants who reported a concurrent relationship in the 3 months prior to each assessment point (13% vs. 15%, χ2 = 1.98). However, there were more respondents reporting concurrent relationships (17–26) and all but one respondent began a new concurrent relationship after ART initiation. Those who reported concurrent relationships (vs. those who did not) also reported more unprotected sex with their HIV-negative or unknown status partners at both time points (ART initiation: 70.6% vs. 29.2%, χ2 = 11.0, P < 0.001; 12-month assessment: 44.0%, vs. 22.5%, χ2 = 5.20, P < 0.05, data not shown in table).

Correlates of High Risk Sexual Behavior 12 Months After ART

Twelve months after ART, there were several factors associated with being in a concurrent relationship and practicing unprotected sex with a partner whose serostatus was HIV-negative or unknown (Table 2). Having a concurrent relationship in the past 12 months was associated with being male (77%, vs. 44%, χ2 = 9.80, P < 0.001), less likely to be living with a partner (50% vs. 71%, χ2 = 4.11, P < 0.05), having unprotected sex (42% vs. 23%, χ2 = 5.2, P < 0.01), less likely to disclose their HIV-serostatus (35% vs. 79%, χ2 = 22.3, P < 0.001), and belief that social and cultural factors encourages unsafe sex (27 vs. 24, t = 2.97, P < 0.01).

Table 2
Socio-economic, clinical, sexual behavior and complacency bivariate associations with 177 sexually active participants at the 12-month assessment point

Having unprotected sex (compared to protected sex) with a partner whose status was HIV negative or unknown was associated with not living with a partner (53% vs. 72%, χ2 = 5.14, P < 0.05), higher stigma scores (57 vs. 54, t = 2.42, P < 0.05), lower disclosure of HIV-serostatus (51% vs. 79%, χ2 = 14.1, P < 0.001), and belief that social and cultural factors encourages unsafe sex (26 vs. 24, t = 2.51, P < 0.05).

Few gender differences in HIV risk behavior and beliefs were found (data not shown in tables). Specifically, men (as compared to women) were more likely to report a concurrent relationship (16% vs. 4%, t = 3.77, P < 0.001), and had lower scores in perceiving HIV as a threat since the availability of ART (18.6 vs. 19.2, t = 3.77, P < 0.01). There were no other important gender differences at 12 months after ART initiation in other sexual behavior variables.

Table 3 illustrates the results from the logistic regression analysis modeling significant associations from the bivariate analysis. For both outcomes, respondents reporting a concurrent relationship or unprotected sex with a partner who was HIV-negative or whose HIV status was unknown were less likely to disclose their HIV status to their sexual partners (OR = 0.07, SE 0.06, 95% CI = 0.01, 0.41; and OR = 0.32 SE 0.16, CI = 0.12, 0.83, respectively).

Table 3
Summary of logistic regression analyses for variables predicting concurrent relationships and unprotected sex with partners of HIV-negative or unknown serostatus 12 months after ART initiation


In this study we assessed change in sexual activity just prior to ART initiation and 12 months after ART initiation, and determined factors associated with changes in sexual behavior. Overall, we found an increase in correct and consistent condom use. However, there also was an increase in the proportion of participants having sex, the total number of partners, and the number of partners with HIV-negative or unknown serostatus. Given that an individual on ART has a lower viral load and thus a lower probability of transmitting HIV to their partners (by 92% in one recent cohort study) [4145], it is not clear as to whether the changes in sexual activity in this population would lead to an increase in secondary transmissions after ART initiation [16]. Mathematical modeling has projected a slight reduction in annual HIV incidence and mortality to less than one case per 1,000 people within 10 years if all persons with HIV could be identified and treated with ART to which they remained highly adherent [16]. However, more advanced modeling would be required to investigate whether the increase in condom use coupled with ART-induced lowered transmission risk—and factoring in ART adherence patterns—would outweigh the increases in sexual activity in this population.

Risk behaviors for the subset of participants who reported concurrent relationships warrant concern. Notably, 96% of the concurrent relationships reported at the 12 month assessment were newly formed, i.e., after initiating ART. While more men than women reported concurrent sexual partnerships, almost half of all persons reporting concurrent sexual partners also reported unprotected sex with their HIV-negative or unknown serostatus partners, and a third were not disclosing their serostatus. This group (both men and women) believed that social and cultural factors encourage men to have multiple sexual partners. Finally, non-disclosure of serostatus was associated with concurrent relationships and having unprotected sex with HIV-negative or unknown serostatus partner.

Though some have questioned its importance [46, 47], concurrency has been shown in mathematical modeling [48] and in some observational studies [49] to propagate the endemic spread of HIV in a population [5052]. At the individual level, the partners of the respondent who has concurrent relationships bear the increased HIV acquisition risk (i.e., one’s own concurrency is a risk for HIV transmission, not acquisition) [53]. The fact that the HIV risk from concurrency is to the partners and not the already HIV-positive respondent must guide appropriate counseling. Prevention with positives messaging to reduce concurrency should focus on taking social and personal responsibility for preventing HIV transmission [54, 55] in concern for partners’ and communities’ well-being, the fact that HIV may still be transmitted even when on ART [56], and the self-protection value of reducing the risk of reinfection with a resistant HIV strain or an STI that may harm the person’s own health [57].

A limitation of this study was the potential of socially desirable responses and under-reporting of sensitive items resulting from our reliance on self-reported behaviors and interviewer–administered questionnaires. Low literacy rates prevent the use of self-administered surveys. A preferred measure would be to adopt technologies (e.g., audio computer-assisted assessments) that may reduce bias, and also lead to more complete data particularly for sensitive questions [58]. Although these techniques do not completely ensure accurate reporting, interviewer–administered surveys would tend to err on the side of reporting fewer high risk behaviors resulting in an overly conservative representation. Since the roll-out of ART in 2004, disclosure of HIV status may have become more socially normalized in the past few years. However the continued persistence of HIV stigma even in high-HIV prevalence communities suggests this may not be the case [59], and may remain a serious impediment to more widespread PLWHA disclosure [60].


Unlike some other recent studies in sub-Saharan Africa [12, 27], we found evidence of increased sexual risk behaviors among a minority of those who had been on ART for 1 year; however, we cannot conclude that risk of secondary HIV transmission has changed. Indeed, given increased condom use and the benefits of treatment on reducing infectivity and the probability of transmission, secondary transmission risk may have decreased. Nonetheless, our findings highlight the need to incorporate ongoing secondary prevention programs for HIV-positive individuals into HIV care settings. Provider-delivered ‘positive prevention’ counseling has been shown in RCTs [61] and meta-analyses [62] in the US to work, and might be effectively adapted for use in other cultural settings [63]. The need for such counseling in high-burden sub-Saharan African settings has been repeatedly emphasized [30, 64]. Since sexual behavior, relationships, and adaptation to HIV disease itself are dynamic processes [65], periodic counseling that individualizes specific barriers, concerns, beliefs and responsibility in regard to risk reduction would help reinforce behavior change over time. Clinics may benefit from incorporating risk behavior screening at each visit to identify those engaging in high-risk behavior and to support risk reduction strategies. For the subset of participants in this study who reported ongoing secondary HIV transmission risk, some risk reduction messages may be more germane than others. This may include ‘loss-framed’ messages [66] that emphasize the self-protection benefits of safer sex (e.g., to avoid HIV reinfection or more commonly, other STIs that can increase viral load) [57]. There also is suggestive evidence that unsafe sex is associated with nondisclosure [6769] and ART non-adherence [70], and conversely that disclosure can be associated with reduced sexual transmission risk behaviors [7173].

Secondly, perceived stigma, non-disclosure of serostatus to sexual partners, and the belief that social cultural factors promote unsafe sexual practice (as has been noted elsewhere) [74], call for a culturally appropriate social marketing campaign to help change community-level beliefs and norms. For example, the message of “zero grazing” may have been a powerful factor in reducing Uganda’s earlier HIV prevalence in the early 1990s [75]. Finally, correct and consistent condom use was seen in Uganda and provides encouraging support that clinic-delivered support can have a beneficial impact. Effective prevention with positive strategies must consider a combination of biomedical and behavioral interventions that focus on the unique characteristics of specific populations.


This work was supported in part by the Stroum Endowed Minority Dissertation Fellowship and the Indigenous Wellness Research Institute funding to Pearson, 5 K01 PS000066 funding to Kurth, the Sociobehavioral and Prevention Research Core at the Center for AIDS Research, University of Washington (NIH/NIAID P30 AI27757) and K99 HD057533 to Cassels, PEPFAR and TAP funding Grant No. 1440/TAP:HIV-AIDS/MS-DPC/GACOPI/04 to Gloyd, Micek, and Montoya. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the University of Washington, the Mozambique Ministry of Health, or the NIH.


Part of the data were presented at the XVII International AIDS Conference, Mexico City, 3–8 August 2008.

Contributor Information

Cynthia R. Pearson, School of Social Work, Indigenous Wellness and Research Institute, University of Washington, Seattle, WA 98195-1525, USA.

Susan Cassels, Center for AIDS Research, University of Washington, Seattle, WA, USA.

Ann E. Kurth, Center for AIDS Research, University of Washington, Seattle, WA, USA. School of Nursing, University of Washington, Seattle, WA, USA. Department of Global Health, University of Washington, Seattle, WA, USA.

Pablo Montoya, Department of Global Health, University of Washington, Seattle, WA, USA. Health Alliance International, Seattle, WA, USA. Health Alliance International, Beira, Mozambique.

Mark A. Micek, Department of Global Health, University of Washington, Seattle, WA, USA. Health Alliance International, Seattle, WA, USA. Health Alliance International, Beira, Mozambique.

Stephen S. Gloyd, Department of Global Health, University of Washington, Seattle, WA, USA. Health Alliance International, Seattle, WA, USA. Health Alliance International, Beira, Mozambique.


1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853–860. [PubMed]
2. Colebunders R, Verdonck K, Nachega J, Kothari P. Impact of new developments in antiretroviral treatments on AIDS patient care in resource-poor countries. AIDS Patient Care STDs. 2000;14:251–257. [PubMed]
3. De Gruttola V, Wulfsohn M, Fischl MA, Tsiatis A. Modeling the relationship between survival and CD4 lymphocytes in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1993;6:359–365. [PubMed]
4. Bangsberg DR, Hecht FM, Clague H, Charlebois ED, Ciccarone D, Chesney M, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435–442. [PubMed]
5. Hogg RS, Heath KV, Yip B, Craib KJP, O’Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279:450–454. [PubMed]
6. Barroso PF, Schechter M, Gupta P, Bressan C, Bomfim A, Harrison LH. Adherence to antiretroviral therapy and persistence of HIV RNA in semen. J Acquir Immune Defic Syndr. 2003;32:435–440. [PubMed]
7. Cu-Uvin S, Snyder B, Harwell JI, et al. Association between paired plasma and cervicovaginal lavage fluid HIV-1 RNA levels during 36 months. J Acquir Immune Defic Syndr. 2006;42:584–587. [PubMed]
8. UNAIDS, WHO. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO); 2007. 07 AIDS epidemic update.
9. Vanable P, Ostrow D, McKirnan D, Taywaditep K, Hope B. Impact of combination therapies on HIV risk perceptions and sexual risk among HIV-positive and HIV-negative gay and bisexual men. Health Psychol. 2000;19:134–145. [PubMed]
10. Elford J. HIV treatment optimism and high-risk sexual behaviour among gay men: the attributable population risk. AIDS. 2004;18:2216–2217. [PubMed]
11. Valdiserri RO. Mapping the roots of HIV/AIDS complacency: implications for program and policy development. AIDS Educ Prev. 2004;16:426–439. [PubMed]
12. Bunnell R, Ekwaru JP, Solberg P, Wamai N, Bikaako-Kajura W, Were W, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS. 2006;20:85–92. [PubMed]
13. Wood E, Braitstein P, Montanerr JS, et al. Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa. Lancet. 2000;355:2095–2100. [PubMed]
14. Das-Douglas M, Chu S, Santos G-M, Scheer S, McFarland W, Vittinghoff E, Colfax G. Decreases in community viral load are associated with a reduction in new HIV diagnoses in San Francisco. Paper # 33. 17th conference on retroviruses and opportunistic infections; San Francisco. 2010. Feb 16–19,
15. Montaner J, Wood E, Kerr T, Yip B, Lima V, Shannon K, et al. Association of expanded HAART coverage with a decrease in new HIV diagnoses, particularly among Injection drug users in British Columbia, Canada. Paper 88LB. 17th conference on retroviruses and opportunistic infections; San Francisco. 2010.
16. Granich R, Crowley S, Vitoria M, Lo YR, Souteyrand Y, Dye C, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;13:1. [PMC free article] [PubMed]
17. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. Epub 2008 Nov 2027. [PubMed]
18. Blower S, Bodine E, Kahn J, et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS. 2005;19:1–14. [PubMed]
19. CDC. vol 18. Atlanta: U.S. Department of Health and Human Services, CDC; 2008. HIV/AIDS surveillance report, 2006; pp. 1–55.
20. Stolte IG, Dukers NH, Geskus RB, Coutinho RA, de Wit JB. Homosexual men change to risky sex when perceiving less threat of HIV/AIDS since availability of highly active antiretroviral therapy: a longitudinal study. AIDS. 2004;18:303–309. [PubMed]
21. Rietmeijer CA, Patnaik JL, Judson FN, Douglas JM., Jr Increases in gonorrhea and sexual risk behaviors among men who have sex with men: a 12-year trend analysis at the Denver Metro Health Clinic. Sex Transm Dis. 2003;30:562–567. [PubMed]
22. Stolte IG, Dukers NH, De Wit JB, Fennema JS, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Dis. 2001;77:184–186. [PMC free article] [PubMed]
23. Klausner JD, Kent CK, Wong W, McCright J, Katz MH. The public health response to epidemic syphilis, San Francisco, 1999–2004. Sex Transm Dis. 2005;32:S11–S18. [PubMed]
24. Pearson CR, Kurth AE, Cassels S, Martin DP, Simoni JM, Hoff P, et al. Modeling HIV transmission risk among Mozambicans prior to their initiating highly active antiretroviral therapy. AIDS Care. 2007;19:594–604. [PubMed]
25. Diabate S, Alary M, Koffi CK. Short-term increase in unsafe sexual behaviour after initiation of HAART in Cote d’Ivoire. AIDS. 2008;22:154–156. [PubMed]
26. Eisele TP, Mathews C, Chopra M, Brown L, Silvestre E, Daries V, et al. High levels of risk behavior among people living with HIV Initiating and waiting to start antiretroviral therapy in Cape Town South Africa. AIDS Behav. 2008;12:570–577. [PubMed]
27. McClelland RS, Graham SM, Richardson BA, Peshu N, Masese LN, Wanje GH, et al. Treatment with antiretroviral therapy is not associated with increased sexual risk behavior in Kenyan female sex workers. AIDS. 2010;24:891–897. [PMC free article] [PubMed]
28. Moatti JP, Prudhomme J, Traore DC, Juillet-Amari A, Akribi HA, Msellati P. Access to antiretroviral treatment and sexual behaviours of HIV-infected patients aware of their serostatus in Cote d’Ivoire. AIDS. 2003;17:S69–S77. [PubMed]
29. Bateganya M, Colfax G, Shafer LA, Kityo C, Mugyenyi P, Serwadda D, et al. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral-naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS. 2005;19:760–768. [PubMed]
30. Eisele TP, Mathews C, Chopra M, Lurie MN, Brown L, Dewing S, et al. Changes in risk behavior among HIV-positive patients during their first year of antiretroviral therapy in Cape Town South Africa. AIDS Behav. 2009;13:1097–1105. Epub 2008 Oct 1010. [PubMed]
31. Peltzer K, Ramlagan S. Safer sexual behaviours after 1 year of antiretroviral treatment in KwaZulu-Natal, South Africa: a prospective cohort study. Sex Health. 2010;7:135–141. [PubMed]
32. Kaida A, Gray G, Bastos FI, Andia I, Maier M, McIntyre J, et al. The relationship between HAART use and sexual activity among HIV-positive women of reproductive age in Brazil, South Africa, and Uganda. AIDS Care. 2008;20:21–25. [PubMed]
33. Pearson CR, Micek M, Simoni JM, Matediana E, Martin DP, Gloyd S. Modified directly observed therapy to facilitate highly active antiretroviral therapy adherence in Beira, Mozambique. Development and implementation. J Acquir Immune Defic Syndr. 2006;43:S134–S141. [PubMed]
34. Pearson CR, Micek MA, Simoni JM, Hoff PD, Matediana E, Martin DP, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;9:238–244. [PubMed]
35. Kelly JA, Kalichman SC. Reinforcement value of unsafe sex as a predictor of condom use and continued HIV/AIDS risk behavior among gay and bisexual men. Health Psychol. 1998;17:328–335. [PubMed]
36. Kennedy C, O’Reilly K, Medley A, Sweat M. The impact of HIV treatment on risk behaviour in developing countries: a systematic review. AIDS Care. 2007;19:707–720. [PubMed]
37. Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24:518–529. [PubMed]
38. Holzemer WL, Makoae M, Greeff PS, Dlamini PS, Kohi ML, Chirwa ML, et al. Measuring HIV stigma for PLHAs and nurses over time in five African countries. SAHARA J. 2009;6:76–82. [PMC free article] [PubMed]
39. Genberg BL, Hlavka Z, Konda KA, Maman S, Chariyalertsak S, Chingono A, et al. A comparison of HIV/AIDS-related stigma in four countries: negative attitudes and perceived acts of discrimination towards people living with HIV/AIDS. Soc Sci Med. 2009;68:2279–2287. [PubMed]
40. Brown RL, Leonard T, Rounds LA, Papasouliotis O. A two-item screening test for abuse of alcohol and other drug problems. J Fam Pract. 1997;44:151–160. [PubMed]
41. Sullivan P, et al. Reduction of HIV transmission risk and high risk sex while prescribed ART: results from discordant couples in Rwanda and Zambia. 16th conference on retroviruses and opportunistic infections; Montreal. 2009.
42. Reynolds S, et al. ART reduced the rate of sexual transmission of HIV among HIV-discordant couples in rural Rakai, Uganda. 16th conference on retroviruses and opportunistic infections; Montreal. 2009.
43. Porco TC, Martin JN, Page-Shafer KA, et al. Decline in infectivity following the introduction of highly active antiretroviral therapy. AIDS. 2004;18:81–88. [PMC free article] [PubMed]
44. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23:1397–1404. [PubMed]
45. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–2098. Epub 2010 May 2026. [PMC free article] [PubMed]
46. Lurie M, Rosenthal S, Williams B. Concurrency driving the African HIV epidemics: where is the evidence? Lancet. 2009;374:1420. author reply 1420–1421. [PubMed]
47. Lurie MN, Rosenthal S. Concurrent partnerships as a driver of the HIV epidemic in sub-Saharan Africa? The evidence is limited. AIDS Behav. 2010;14:17–24. discussion 25–18. [PMC free article] [PubMed]
48. Rothenberg R. HIV transmission networks. Curr Opin HIV AIDS. 2009;4:260–265. [PMC free article] [PubMed]
49. Helleringer S, Kohler HP, Kalilani-Phiri L. The association of HIV serodiscordance and partnership concurrency in Likoma Island (Malawi) AIDS. 2009;23:1285–1287. [PMC free article] [PubMed]
50. Mah TL, Halperin DT. Concurrent sexual partnerships and the HIV epidemics in africa: evidence to move forward. AIDS Behav. 2008 Epub ahead of print. [PubMed]
51. Morris M, Goodreau SM, Moody J. Sexual networks, concurrency, and STD/HIV. In: Holmes KK, editor. Sexually transmitted diseases. New York: McGraw-Hill; 2007.
52. Morris M, Kurth AE, Hamilton DT, Moody J, Wakefield S. Concurrent partnerships and HIV prevalence disparities by race: linking science and public health practice. Am J Public Health. 2009;99:1023–1031. [PubMed]
53. Morris M, Kretzschmar M. Concurrent partnerships and the spread of HIV. AIDS. 1997;11:641–683. [PubMed]
54. King R, Lifshay J, Nakayiwa S, Katuntu D, Lindkvist P, Bunnell R. The virus stops with me: HIV-infected Ugandans’ motivations in preventing HIV transmission. Soc Sci Med. 2009;68:749–757. [PubMed]
55. Kielmann K, Cataldo F. Tracking the rise of the “expert patient” in evolving paradigms of HIV care. AIDS Care. 2010;22:21–28. [PubMed]
56. Atuyambe L, Neema S, Otolok-Tanga E, Wamuyu-Maina G, Kasasa S, Wabwire-Mangen F. The effects of enhanced access to antiretroviral therapy: a qualitative study of community perceptions in Kampala City, Uganda. Afr Health Sci. 2008;8:13–19. [PubMed]
57. McClelland L, Wanje G, Kashonga F, McClelland RS, Kiarie J, Mandaliya K, et al. Understanding the risk context of HIV and sexual behaviour following antiretroviral therapy rollout in a population of high-risk women in Kenya. AIDS Educ Behav. In review.
58. Kurth AE, Martin DP, Golden MG, Weiss N, Heagerty P, Handsfield HH, et al. A comparison of sexually transmitted infection risk reporting in audio computer-assisted self- interviews and clinician interviews. Sex Transm Dis. 2004;31:719–726. [PubMed]
59. Gilbert L, Walker L. ‘My biggest fear was that people would reject me once they knew my status’: stigma as experienced by patients in an HIV/AIDS clinic in Johannesburg, South Africa. Health Soc Care Community. 2010;18:139–146. [PubMed]
60. Gebrekristos HT, Lurie MN, Mthethwa N, Karim QA. Disclosure of HIV status: experiences of patients enrolled in an integrated TB and HAART pilot programme in South Africa. Afr J AIDS Res. 2009;8:1–6. [PMC free article] [PubMed]
61. Myers JJ, Shade SB, Rose CD, Koester K, Maiorana A, Malitz FE, et al. Interventions delivered in clinical settings are effective in reducing risk of HIV transmission among people living with HIV: results from the Health Resources and Services Administration (HRSA)’s Special Projects of National Significance initiative. AIDS Behav. 2010;14:483–492. [PMC free article] [PubMed]
62. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004;292:224–236. [PubMed]
63. Dawson Rose C, Gutin SA, Reyes M. Adapting positive prevention interventions for international settings: applying U.S. evidence to epidemics in developing countries. J Assoc Nurses AIDS Care. 2010;9:9. [PubMed]
64. Bunnell R, Mermin J, De Cock KM. HIV prevention for a threatened continent: implementing positive prevention in Africa. JAMA. 2006;296:855–858. [PubMed]
65. Eaton LA, Kalichman SC. Changes in transmission risk behaviors across stages of HIV disease among people living with HIV. J Assoc Nurses AIDS Care. 2009;20:39–49. [PMC free article] [PubMed]
66. Richardson JL, Milam JAM, Stoyanoff S, Bolan R, Weiss J, et al. Effect of brief safer-sex counseling by medical providers to HIV-1 seropositive patients: a multi-clinic assessment. AIDS. 2004;18:1179–1186. [PubMed]
67. Luchters S, Sarna A, Geibel S, Chersich MF, Munyao P, Kaai S, et al. Safer sexual behaviors after 12 months of antiretroviral treatment in Mombasa, Kenya: a prospective cohort. AIDS Patient Care STDS. 2008;22:587–594. [PubMed]
68. Deribe K, Woldemichael K, Wondafrash M, Haile A, Amberbir A. Disclosure experience and associated factors among HIV positive men and women clinical service users in Southwest Ethiopia. BMC Public Health. 2008;8:81. [PMC free article] [PubMed]
69. Simbayi LC, Kalichman SC, Strebel A, Cloete A, Henda N, Mqeketo A. Disclosure of HIV status to sex partners and sexual risk behaviours among HIV-positive men and women, Cape Town, South Africa. Sex Transm Infect. 2007;83:29–34. [PMC free article] [PubMed]
70. Harding R, Lampe FC, Norwood S, Date HL, Clucas C, Fisher M, et al. Symptoms are highly prevalent among HIV outpatients and associated with poor adherence and unprotected sexual intercourse. Sex Transm Infect. 2010;15:15. [PubMed]
71. Wong LH, Rooyen HV, Modiba P, Richter L, Gray G, McIntyre JA, et al. Test and tell: correlates and consequences of testing and disclosure of HIV status in South Africa (HPTN-043 Project Accept) J Acquir Immune Defic Syndr. 2009;50:215–222. [PMC free article] [PubMed]
72. Loubiere S, Peretti-Watel P, Boyer S, Blanche J, Abega SC, Spire B. HIV disclosure and unsafe sex among HIV-infected women in Cameroon: results from the ANRS-EVAL study. Soc Sci Med. 2009;69:885–891. [PubMed]
73. King R, Katuntu D, Lifshay J, et al. Processes and outcomes of HIV serostatus disclosure to sexual partners among people living with HIV in Uganda. AIDS Behav. 2008;12:232–243. [PubMed]
74. Sarna A, Chersich MF, Okal J, Luchters SMF, Mandaliya KN, Rutenberg N, et al. Changes in sexual risk taking with antiretroviral treatment: influence of context and gender norms in Mombasa, Kenya. Cult Health Sex. 2009;11:783–797. [PubMed]
75. Stoneburner RL, Low-Beer D. Population-level HIV declines and behavioral risk avoidance in Uganda. Science. 2004;304:714–718. [PubMed]